Press release
Oramed Pharmaceuticals Appoints Chief Legal Officer
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed's legal and corporate strategy affairs and provide strategic guidance to the executive team and Board of Directors. \n\"We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer. Netanel's business-minded approach, legal acumen and strong operational skills will be instrumental to Oramed's ongoing progress and success and will further strengthen our executive team,\" stated Oramed Chief Executive Officer, Nadav Kidron. \nMr. Derovan is a highly accomplished executive leader, having spent over 20 years in senior legal positions. Prior to joining Oramed, Mr. Derovan served as executive counsel, corporate and securities, in the legal department of Teva Pharmaceutical Industries Ltd., as senior counsel in the International Corporate and Securities Department of Goldfarb Seligman & Co. and as an associate attorney in the International Corporate Department at Caspi & Co. Mr. Derovan holds an LLB degree from Bar Ilan University in Israel and he is a member of the Israeli Bar Association. \n\"I am thrilled to be joining Oramed at such an exciting time, as the company is approaching a number of important milestones. I look forward to leveraging my skills and working with the entire Oramed team as the company enters the next stage of growth,\" said Mr. Derovan. \nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule...